Global collaboration action for research on existing Malaria therapeutics and clinical development of new antimalarial candidates
The Global collaboration action for research on existing Malaria therapeutics and clinical development of new antimalarial candidates is a Horizon Europe initiative aiming to combat malaria drug resistance and advance new antimalarial treatments. This program supports global partnerships, especially fostering strong representation and research capacity building within Sub-Saharan African countries, to deliver impactful solutions against malaria. It focuses on accelerating clinical development and ensuring affordable access to new health technologies.
Who is Funded for Malaria Research
This section outlines the eligibility criteria for funding, including who can apply, the geographical areas covered by the program, and its core objectives. It targets a broad range of entities dedicated to advancing malaria research and public health outcomes, especially in regions most affected by the disease.
What is Funded in Malaria Therapeutics
This section details the types of projects and activities supported by the funding program, focusing on the clinical development of malaria therapeutics. It outlines the specific research areas and stages of development that are eligible for funding, aiming to advance promising candidates towards registration and public health impact.
Type and Scope of Malaria Funding
This section provides detailed information on the financial support available through the program, including the type of funding instrument and the maximum funding amount per project. It highlights the financial parameters designed to facilitate impactful research and development in malaria therapeutics.
Conditions for Malaria Research Funding
This section outlines the essential rules, regulations, and specific requirements for applicants and beneficiaries participating in the program. It covers consortium composition, exploitation obligations for research results, and other important provisions to ensure effective project implementation and impact.
Application Procedure for Malaria Funding
This section outlines the procedural steps for applying to the program, including submission details and the evaluation process. It provides insights into how proposals are assessed and how decisions are communicated to applicants, emphasizing a two-stage evaluation approach.
Legal Basis of the Funding Program
This section establishes the legal and official foundation of the funding program, identifying the primary authorizations and key regulations that govern its operation. It clarifies the framework within which the program operates and where relevant legal texts can be accessed.
Similar Programs
Funding Overview
Funding Status:
Closed
Maximum Amount:
10,300,000 €
Allocated Budget:
30,900,000 €
Open Until:
31.12.2027
Award Channel:
Framework Programme Call
Region:
European Union (Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Aruba, Bonaire, Curaçao, French Polynesia, French Southern and Antarctic Territories, Greenland, New Caledonia, Saba, Saint Barthélemy, Sint Eustatius, Sint Maarten, St. Pierre and Miquelon, Wallis and Futuna Islands), Sub-Saharan Africa (Benin, Burkina Faso, Cameroon, Côte d’Ivoire, Democratic Republic of the Congo, Ethiopia, Eswatini, Gabon, The Gambia, Ghana, Guinea-Bissau, Guinea-Conakry, Kenya, Liberia, Malawi, Mali, Mozambique, Niger, Nigeria, Republic of the Congo, Rwanda, Senegal, Sierra Leone, Somalia, South Africa, Tanzania, Uganda, Zambia, Zimbabwe), Associated Countries to Horizon Europe (Albania, Armenia, Bosnia and Herzegovina, Canada, Faroe Islands, Georgia, Iceland, Israel, Kosovo, Moldova, Montenegro, New Zealand, North Macedonia, Norway, Serbia, Tunisia, Turkey, Ukraine, United Kingdom), and countries with ongoing association negotiations (Morocco, South Korea, Switzerland).
Sectors:
Healthcare, Medical Technology, Pharmaceutical Industry, Research and Development
Beneficiaries:
Children, pregnant women, infants, immune-compromised individuals, adolescents
Application Type:
Consortium Required
Funding Stages:
Applied Research, Experimental Development, Pilot Testing, Commercialization, Monitoring
Funding Provider
Program Level:
European Union
Funding Body:
European Commission (via Global Health EDCTP3 Joint Undertaking)
Managed By:
Global Health EDCTP3 Joint Undertaking (JU)
Additional Partners:
Contributing partners (academic and research institutions, pharmaceutical and biotechnology companies, public health organizations, hospitals, clinical networks, capacity-building organizations) providing financial and/or in-kind contributions. Collaboration and coordination with the Team Europe Initiative on Manufacturing and Access to Vaccines, medicines and health products (TEI-MAV+) or similar African initiatives is encouraged.
Website: